deferasirox has been researched along with Cirrhosis, Liver in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adel, N; El-Demerdash, E; El-Sherbiny, DA; Mantawy, EM | 1 |
| Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Bridle, KR; Campbell, CM; Clouston, AD; Crawford, DH; de Guzman, CE; Jaskowski, L; Santrampurwala, N; Sobbe, A; Subramaniam, VN | 1 |
| Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Della Pepa, R; Pane, F; Picardi, M; Pugliese, N | 1 |
| Adamidou, D; Daniilidis, A; Gigi, E; Klonizakis, P; Mandala, E; Sinakos, E; Sousos, N; Tsioni, K; Vetsiou, E; Vlachaki, E | 1 |
| Brissot, P; Cappellini, MD; Deugnier, Y; Giannone, V; Griffel, L; Porter, JB; Ropert, M; Turlin, B; Zhang, Y | 1 |
| Adams, PC | 1 |
1 trial(s) available for deferasirox and Cirrhosis, Liver
| Article | Year |
|---|---|
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Topics: Adolescent; Adult; Alanine Transaminase; Benzoates; beta-Thalassemia; Biomarkers; Biopsy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Female; Ferritins; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2011 |
6 other study(ies) available for deferasirox and Cirrhosis, Liver
| Article | Year |
|---|---|
Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach.
Topics: Animals; Concanavalin A; Deferasirox; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Rats; Rats, Sprague-Dawley | 2019 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load | 2017 |
Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
Topics: Actins; Administration, Oral; Animals; Benzoates; Cells, Cultured; Deferasirox; Disease Models, Animal; Gene Expression; Hepatic Stellate Cells; Humans; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Transgenic; Procollagen; Triazoles | 2015 |
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Myelodysplastic Syndromes | 2018 |
Deferasirox improves liver fibrosis in beta-thalassaemia major patients. A five-year longitudinal study from a single thalassaemia centre.
Topics: Adult; beta-Thalassemia; Deferasirox; Female; Follow-Up Studies; Greece; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies | 2018 |
Chelation therapy for secondary iron overload: is the primary effect less iron or less liver fibrosis?
Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Triazoles | 2011 |